Sandoz suspends drug production at Quebec facility
Sandoz Canada said it would shift production at the plant to medically necessary products, the globe and mail reported. The company did not clarify the impacted drugs and
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.